Aquestive Therapeutics, Inc. 8-K

What Happened
Aquestive Therapeutics, Inc. filed an 8-K on June 10, 2026 reporting results from its 2026 Annual Meeting of Stockholders held that day. The company announced election of three Class II directors (terms to 2029), a non‑binding advisory approval of executive compensation for one year ("say-on-pay"), and ratification of KPMG LLP as independent registered public accounting firm for fiscal 2026.

Key Details

• Directors elected (Class II, three-year terms to the 2029 Annual Meeting):
  • Gregory B. Brown, M.D.: 41,373,033 votes for; 1,222,711 abstentions; (no votes against reported).
  • John S. Cochran: 36,914,899 votes for; 5,680,845 abstentions; (no votes against reported).
  • Abigail L. Jenkins: 39,094,166 votes for; 3,501,578 abstentions; (no votes against reported).
• Advisory vote on executive compensation (say-on-pay): approved for one year — 37,798,609 for; 3,192,381 against; 1,604,754 abstaining; broker non‑votes: 37,465,582.
• Appointment of auditor ratified: KPMG LLP was ratified for fiscal year ending Dec. 31, 2026 — 78,804,323 for; 910,690 against; 346,313 abstaining.
• 8-K signed and filed June 10, 2026 by A. Ernest Toth, Jr., Chief Financial Officer.

Why It Matters
These governance votes confirm the board composition and give the company an endorsement (advisory) of its executive pay policy for another year, which can affect investor confidence in management alignment. Ratification of KPMG as auditor ensures continuity in external financial oversight for fiscal 2026. Retail investors tracking corporate governance or planning engagement with the company may view these outcomes as signals of shareholder support and governance stability.